K Number
K113772
Device Name
HPR EMOLLIENT FOAM
Date Cleared
2012-02-09

(49 days)

Product Code
Regulation Number
N/A
AI/MLSaMDIVD (In Vitro Diagnostic)TherapeuticDiagnosticis PCCP AuthorizedThirdparty
Intended Use
HPR™ Emollient Foam is indicated to manage and relieve the burning, itching and pain associated with various types of dermatoses, including atopic dermatitis, allergic contact dermatitis, and radiation dermatitis. HPRTM Emollient Foam also helps to relieve dry, waxy skin by maintaining a moist wound & skin environment, which is beneficial to the healing process.
Device Description
HPR 114 Emollient Foam is a non-sterile, off-white, low odor, fragrance free, topical aerosol foam. When HPR™ Emollient Foam is dispensed, foam is formed. The propellant in the foam dissipates very quickly and the foam is then rubbed on the affected skin. The HPR™ Emollient Foam when applied to diseased skin forms a protective barrier that helps to maintain a moist wound and skin environment. This device is presented as a prescription product that requires the physician to diagnosis of the disease state and prescribes the product.
More Information

Not Found

No
The 510(k) summary describes a topical emollient foam and does not mention any AI or ML components in its intended use, device description, or performance studies.

Yes
The device is indicated to manage and relieve symptoms (burning, itching, pain) associated with various dermatoses and to maintain a moist skin environment for healing, which are therapeutic claims.

No

The device is an emollient foam intended to manage and relieve symptoms associated with dermatoses; it does not diagnose medical conditions. Its use requires a physician's diagnosis.

No

The device description clearly states it is a "topical aerosol foam," which is a physical product applied to the skin, not a software program.

Based on the provided information, this device is not an IVD (In Vitro Diagnostic).

Here's why:

  • Intended Use: The intended use is to manage and relieve symptoms associated with various dermatoses by topical application to the skin. This is a therapeutic and symptomatic relief function, not a diagnostic one.
  • Device Description: The device is a topical aerosol foam applied to the skin. It forms a protective barrier and maintains a moist environment. This is a physical and therapeutic action, not a diagnostic test performed on a sample from the body.
  • No mention of in vitro testing: There is no indication that this device is used to examine specimens derived from the human body (like blood, urine, tissue, etc.) to provide information for diagnosis, monitoring, or screening.

IVD devices are specifically designed to perform tests on samples taken from the body to provide diagnostic information. This device is applied to the body for therapeutic and symptomatic relief.

N/A

Intended Use / Indications for Use

HPRTM Emollient Foam is indicated to manage and relieve the burning, itching, and pain experienced with various types of dermatoses, including atopic dermatitis, allergic contact dermatitis and radiation dermatitis. HPR™ Emollient Foam also helps to relieve dry, waxy skin by maintaining a moist wound & skin environment, which is beneficial to the healing process.

Product codes

FRO

Device Description

HPR 114 Emollient Foam is a non-sterile, off-white, low odor, fragrance free, topical aerosol foam. When HPR™ Emollient Foam is dispensed, foam is formed. The propellant in the foam dissipates very quickly and the foam is then rubbed on the affected skin. The HPR™ Emollient Foam when applied to diseased skin forms a protective barrier that helps to maintain a moist wound and skin environment. This device is presented as a prescription product that requires the physician to diagnosis of the disease state and prescribes the product.

Mentions image processing

Not Found

Mentions AI, DNN, or ML

Not Found

Input Imaging Modality

Not Found

Anatomical Site

Not Found

Indicated Patient Age Range

Not Found

Intended User / Care Setting

Not Found

Description of the training set, sample size, data source, and annotation protocol

Not Found

Description of the test set, sample size, data source, and annotation protocol

Not Found

Summary of Performance Studies

Functional and performance testing has been conducted to assess the safety and effectiveness of HPR™ Emollient Foam and all results are satisfactory.

Key Metrics

Not Found

Predicate Device(s)

K083024

Reference Device(s)

Not Found

Predetermined Change Control Plan (PCCP) - All Relevant Information

Not Found

N/A

0

K 113772

FEB - 9 2012

510(k) Summary

Date Prepared: December 19, 2011

| 1. | Owner's Name: | PruGen, IP Holdings Inc.
8714 E. Vista Bonita Drive
Scottsdale, AZ 85255 |
|----|-----------------|-----------------------------------------------------------------------------------------------|
| | Contact Person: | Bhiku Patel, Ph.D.
(T): 480-585-0122 ext. 3
(F): 480-393-5873
(E): bpatel@prugen.com |

HPRTM Emollient Foam Proprietarv Name: 2. Dressing, Wound & Burn, Hydrogel w/ Drug or Biologic Common Name: Classification Name: Dressing, Wound & Burn, Hydrogel w/ Drug or Biologic (Product Code MGQ)

Substantially Equivalent Device: 3.

PruGen IP Holdings, Inc. believes that HPR™ Emollient Foam is substantially equivalent to the following currently marketed device: Hylatopic ™ Emollient Foam cleared under K083024.

Device Description: 4.

HPR 114 Emollient Foam is a non-sterile, off-white, low odor, fragrance free, topical aerosol foam. When HPR™ Emollient Foam is dispensed, foam is formed. The propellant in the foam dissipates very quickly and the foam is then rubbed on the affected skin. The HPR™ Emollient Foam when applied to diseased skin forms a protective barrier that helps to maintain a moist wound and skin environment. This device is presented as a prescription product that requires the physician to diagnosis of the disease state and prescribes the product.

Intended Use of the Device: ડ.

HPRTM Emollient Foam is indicated to manage and relieve the burning, itching, and pain experienced with various types of dermatoses, including atopic dermatitis, allergic contact dermatitis and radiation dermatitis. HPR™ Emollient Foam also helps to relieve dry, waxy skin by maintaining a moist wound & skin environment, which is beneficial to the healing process.

Summary of Technical Characteristics of Device compared to Predicate Devices 6.

The predicate device referenced is a non-sterile foam that is applied topically to relieve the symptoms of various dermatoses. When HPR™ Emollient Foam is dispensed, foam is formed. The propellant in the foam dissipates very quickly and the foam is then rubbed on the affected skin. The rubbed in product is equivalent to gel or cream.

1

Testing and Conclusions: 7.

Functional and performance testing has been conducted to assess the safety and effectiveness of HPR™ Emollient Foam and all results are satisfactory.

2

Image /page/2/Picture/1 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo consists of a stylized eagle with its wings spread, and the words "DEPARTMENT OF HEALTH & HUMAN SERVICES • USA" are arranged in a circle around the eagle. The eagle is depicted in a simple, black-and-white design.

Food and Drug Administration 10903 New Hampshire Avenue Document Control Room -WO66-G609 Silver Spring, MD 20993-0002

PruGen. IP Holdings Inc. % Bhiku Patel, Ph.D. 8714 East Vista Bonita Drive Scottsdale, Arizona 85255

FEB - 9 2012

Re: K113772

Trade/Device Name: HPR™ Emollient Foam Regulatory Class: Unclassified Product Code: FRO Dated: January 24, 2012 Received: January 31, 2012

Dear Dr. Patel:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you; however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical

3

Page 2 – Bhiku Patel, Ph.D.

device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please go to http://www.fda.gov/AboutFDA/CentersOffices/CDRH/CDRHOffices/ucm115809.htm for the Center for Devices and Radiological Health's (CDRH's) Office of Compliance. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to

http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.

You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address

http://www.fda.gov/MedicalDevices/Resourcesfor You/Industry/default.htm.

Sincerely yours.

Pon Dof-b
Nof L.

Mark N. Melkers Director Division of Surgical, Orthopedic and Restorative Devices Office of Device Evaluation Center for Devices and Radiological Health

Enclosure

4

Date: December 19, 2011

INDICATIONS FOR USE

Device Trade Name: HPR™ Emollient Foam

510(k) number: K113772

Rx Only

FOR TOPICAL DERMATOLOGICAL USE ONLY

HPR™ Emollient Foam is indicated to manage and relieve the burning, itching and pain associated with various types of dermatoses, including atopic dermatitis, allergic contact dermatitis, and radiation dermatitis. HPRTM Emollient Foam also helps to relieve dry, waxy skin by maintaining a moist wound & skin environment, which is beneficial to the healing process.

Prescription Use X (21 CFR 801 Subpart D) Over-The-Counter (21 CFR 801 Subpart C)

Concurrence of CDRH, Office of Device Evaluation (ODE)

Daniel Ksonetu MKM

Page 1 of

(Division Sign-Off) (Division Sign-On)
Division of Surgical, Orthopedic, Ivision of Sinces

510(k) Number K113772